Adverum Biotechnologies, Inc.
ADVM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $106,396 | $45,172 | $91,499 | $97,594 |
| - Cash | $26,060 | $42,418 | $49,161 | $60,652 |
| + Debt | $88,940 | $92,221 | $93,178 | $91,705 |
| Enterprise Value | $169,276 | $94,975 | $135,516 | $128,647 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$465 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$47,187 | -$49,320 | -$47,538 | -$61,407 |
| % Margin | – | – | – | – |
| Net Income | -$47,652 | -$49,191 | -$47,019 | -$60,530 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.03 | -2.34 | -2.25 | -1.96 |
| % Growth | 13.2% | -4% | -14.8% | – |
| Operating Cash Flow | -$28,115 | -$38,767 | -$42,771 | -$28,249 |
| Capital Expenditures | -$142 | -$120 | -$220 | -$61 |
| Free Cash Flow | -$28,257 | -$38,887 | -$42,991 | -$28,310 |